This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
inflammatory-bowel-disease
Inflammatory Bowel Disease
Chronic intestinal inflammation: Crohn's disease (transmural, any GI) and ulcerative colitis (mucosal, colon only). TNF-alpha, IL-12/23, and JAK-STAT drive inflammation. Anti-TNF (infliximab), anti-IL-23 (risankizumab), and anti-integrin (vedolizumab) are mainstay biologics.
Entry Metadata
| Field | Value |
|---|---|
| ID | inflammatory-bowel-disease |
| Name | Inflammatory Bowel Disease |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390(10114):2769-2778. · PubMed 29050646
- Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699-710. · PubMed 23964932
- Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2019;381(13):1201-1214. · PubMed 31553834